title: Intraocular avastin (bevacizumab) for neovascularisation of the iris and neovascular glaucoma.
abstract: BACKGROUND
  The aim of this study was to determine the effectiveness of intraocular injections of bevacizumab for neovascularisation of the iris and neovascular glaucoma.
  
  
  METHODS
  Three patients with neovascularisation of the iris due to various causes were recruited.
  
  
  METHODS
  Patients were treated with intraocular bevacizumab.
  
  
  RESULTS
  Neovascularisation of the iris was noted to have completely regressed as early as 3 days after the injection and in all the patients (100%) within 8 days after injection. They were followed up for at least 1 month with no clinical evidence of recurrence. Visual acuity remained stable or improved, and the intraocular pressure was controlled in all the 3 patients' eyes. Vitreous haemorrhage also cleared. No signs of inflammation or complications were observed.
  
  
  CONCLUSIONS
  Intraocular injection of bevacizumab is effective and safe for patients with neovascularisation of the iris and neovascular glaucoma with or without vitreous haemorrhage.
authors.affiliation: Vitreoretina Department, Singapore National Eye Centre, Singapore. jacob.cheng@singhealth.com.sg
authors.forename: Jacob Y C
authors.initials: JY
authors.lastname: Cheng
authors.forename: Doric W K
authors.initials: DW
authors.lastname: Wong
authors.forename: Chong Lye
authors.initials: CL
authors.lastname: Ang
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015355:Glaucoma, Neovascular / Q000188:drug therapy*; D006801:Humans; D007498:Iris / Q000098:blood supply*; D008297:Male
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab